GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Cyclically Adjusted PB Ratio

Kintara Therapeutics (STU:3DMA) Cyclically Adjusted PB Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kintara Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kintara Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Cyclically Adjusted PB Ratio Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Kintara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Cyclically Adjusted PB Ratio falls into.



Kintara Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kintara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Kintara Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.072/131.7762*131.7762
=-0.072

Current CPI (Mar. 2024) = 131.7762.

Kintara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 10.152 100.428 13.321
201412 76.050 99.070 101.157
201503 43.943 99.621 58.127
201506 -49.721 100.684 -65.075
201509 -35.866 100.392 -47.079
201512 -6.727 99.792 -8.883
201603 -39.233 100.470 -51.458
201606 -74.939 101.688 -97.112
201609 -111.668 101.861 -144.463
201612 -171.347 101.863 -221.666
201703 -209.807 102.862 -268.783
201706 4.721 103.349 6.020
201709 120.745 104.136 152.794
201712 66.497 104.011 84.248
201803 21.846 105.290 27.342
201806 -18.463 106.317 -22.884
201809 -51.249 106.507 -63.408
201812 -56.760 105.998 -70.564
201903 -82.823 107.251 -101.763
201906 -34.692 108.070 -42.302
201909 8.846 108.329 10.761
201912 2.672 108.420 3.248
202003 -4.288 108.902 -5.189
202006 -17.595 108.767 -21.317
202009 -4.521 109.815 -5.425
202012 -6.752 109.897 -8.096
202103 -4.771 111.754 -5.626
202106 -5.515 114.631 -6.340
202109 4.862 115.734 5.536
202112 1.174 117.630 1.315
202203 -2.917 121.301 -3.169
202206 -0.548 125.017 -0.578
202209 -1.835 125.227 -1.931
202212 -2.357 125.222 -2.480
202303 -3.786 127.348 -3.918
202306 -5.407 128.729 -5.535
202309 -6.780 129.860 -6.880
202312 -0.939 129.419 -0.956
202403 -0.072 131.776 -0.072

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kintara Therapeutics  (STU:3DMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kintara Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines